StockTipsArenaBeta

SELL Lupin Limited — ICICI Securities

SELLLupin Limited

byICICI SecuritiesHorizon: NA (inferred 1 year)9 Aug 2026via Institutional / Brokerage Research

Entry₹2,360Inferred
Target₹2,200
Total upside +6.78% (call closed)
Stop lossNot given
Exit₹2,20021 Aug 2026, 12:08 pm
Target hit+6.78%0.00%upside left
Follow ICICI Securities for new calls(68% target hit, 1025 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 14 active Long-term calls on LUPINSee 36 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Aug 2026
8 supporting2 neutral39 opposing
Supports the SELL call (8)

US tariff threat drags Nifty Pharma 1.3% lower at close; Lupin, PPL Pharma lead decline

NewsHbl·22 Jul · 4w ago

(opens in new tab)

Top Gainers & Losers on 22 July: Bandhan Bank, PG Electroplast, Lupin, Delhivery, Voltas, IndiGo among top losers

NewsLivemint·22 Jul · 4w ago

(opens in new tab)

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 4w ago

(opens in new tab)
Neutral / worth noting (2)

Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead — Check Target Price

NewsNdtv-Profit·10 Aug · 2w ago

(opens in new tab)
Weighs against the SELL call (39)

Lupin arm gets exclusive rights to presbyopia treatement drug in Europe

NewsCnbc-Tv18·20 Aug · today

(opens in new tab)

Lupin Ltd's wholly owned subsidiary, VISUfarma B.V., has entered into an Exclusive License Agreement with Visus Therapeutics, Inc.

BSE · Company Update·20 Aug · yesterday

(opens in new tab)

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

NewsEt-Markets·18 Aug · 3d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Pitolisant Tablets. This approval is a significant step for the company's pharmaceutical offerings.

BSE · Company Update·17 Aug · 3d ago

(opens in new tab)

Lupin Limited announced that the U.S. FDA has approved its Pitolisant Tablets. This approval is a significant step for the company's product portfolio.

NSE · Press Release·17 Aug · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.